TuisSNG • LON
add
Synairgen plc
Vorige sluiting
GBX 4,71
Dagwisseling
GBX 4,37 - GBX 4,75
Jaarwisseling
GBX 3,00 - GBX 10,88
Markkapitalisasie
8,93 m GBP
Gemiddelde volume
162,56 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
LON
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (GBP) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 1,95 m | -29,14% |
Netto inkomste | -1,63 m | 31,28% |
Netto winsgrens | — | — |
Wins per aandeel | — | — |
EBITDA | -1,95 m | 28,75% |
Effektiewe belastingkoers | 10,92% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (GBP) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 8,59 m | -19,19% |
Totale bates | 10,64 m | -43,12% |
Totale aanspreeklikheid | 1,08 m | -60,69% |
Totale ekwiteit | 9,56 m | — |
Uitstaande aandele | 201,37 m | — |
Prys om te bespreek | 0,94 | — |
Opbrengs op bates | -45,90% | — |
Opbrengs op kapitaal | -51,07% | — |
Kontantvloei
Netto kontantverandering
| (GBP) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -1,63 m | 31,28% |
Kontant van bedrywe | -1,84 m | 30,36% |
Kontant van beleggings | 882,00 k | 88 100,00% |
Kontant van finansiering | — | — |
Netto kontantverandering | -962,50 k | 63,64% |
Beskikbare kontantvloei | -1,13 m | 24,89% |
Meer oor
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.
Richard Marsden was appointed chief executive officer in September 2009. Wikipedia
Gestig
2003
Webwerf
Werknemers
36
